Last reviewed · How we verify

GC3110A vaccine — Competitive Intelligence Brief

GC3110A vaccine (GC3110A vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic cancer vaccine. Area: Oncology.

phase 3 Therapeutic cancer vaccine Oncology Biologic Live · refreshed every 30 min

Target snapshot

GC3110A vaccine (GC3110A vaccine) — Green Cross Corporation. GC3110A is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GC3110A vaccine TARGET GC3110A vaccine Green Cross Corporation phase 3 Therapeutic cancer vaccine
CPA CPA ImmunoVaccine Technologies, Inc. (IMV Inc.) marketed Therapeutic cancer vaccine
VEC VEC Centre Leon Berard marketed Therapeutic cancer vaccine
D-cure D-cure KU Leuven marketed Therapeutic cancer vaccine
HSPPC-96 or Oncophage HSPPC-96 or Oncophage Agenus Inc. phase 3 Autologous therapeutic cancer vaccine Tumor-associated antigens presented via Hsp96 complexes
Begrivac® Begrivac® Chiltern Pesquisa Clinica Ltda phase 3 Therapeutic cancer vaccine Patient-specific tumor neoantigens
MSB0010718C MSB0010718C Istituto Oncologico Veneto IRCCS phase 3 Therapeutic cancer vaccine Patient-specific tumor neoantigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic cancer vaccine class)

  1. GlaxoSmithKline · 2 drugs in this class
  2. Green Cross Corporation · 2 drugs in this class
  3. Chiang Mai University · 1 drug in this class
  4. Chiltern Pesquisa Clinica Ltda · 1 drug in this class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
  6. Galena Biopharma, Inc. · 1 drug in this class
  7. Genocea Biosciences, Inc. · 1 drug in this class
  8. ImmunoVaccine Technologies, Inc. (IMV Inc.) · 1 drug in this class
  9. Istituto Oncologico Veneto IRCCS · 1 drug in this class
  10. KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GC3110A vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/gc3110a-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: